Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 7/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 6/20 | 0.59 |
| ▸ | HTR3B | O95264 | 6/20 | 0.59 |
| ▸ | HTR3A | P46098 | 6/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 6/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 6/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819761 | 1.00 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRNA7HTR3E | |
| SCHEMBL2819382 | 1.00 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRNA7HTR3E | |
| SCHEMBL2821688 | 1.00 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRNA7HTR3E | |
| SCHEMBL1090629 | 0.86 | CHRNA7 (0.72) | CHRM3CHRM2CHRM1CHRNA7HTR3E | |
| Hydrochloric Acid SCHEMBL9646131 | 0.85 | CHRNA7 (0.70) | CHRM3CHRM2CHRM1CHRNA7HTR3E | |
| SCHEMBL9732560 | 0.82 | CHRNA7 (0.60) | CHRM3CHRM2CHRM1CHRNA7HTR3E | |
| SCHEMBL2819828 | 0.81 | CHRNA7 (0.52) | CHRM3CHRM2CHRM1CHRNA7HTR3E | |
| SCHEMBL7381736 | 0.78 | CHRNA7 (0.63) | CHRM3CHRM2CHRM1CHRNA7HTR3E | |
| SCHEMBL5202023 | 0.76 | CHRM3 (0.60) | CHRM3CHRM2CHRM1CHRNA7HTR3E | |
| SCHEMBL2818959 | 0.75 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRNA7HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519933-B1 | QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL SA (ES) | 2010-05-12 | — | — | EP | claimed |
| US-20080234316-A1 | Quinuclidine Amide Derivatives | ALMIRALL AG | 2008-09-25 | — | — | US | claimed |
| US-20060167042-A1 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | LABORATORIOS ALMIRALL S.A. (ES) | 2006-07-27 | — | — | US | claimed |
| JP-2005533826-A | — | — | 2005-11-10 | — | — | JP | claimed |
| EP-1519933-A1 | QUINUCLIDINE AMIDE DERIVATIVES | Almirall Prodesfarma AG (CH) | 2005-04-06 | — | — | EP | claimed |
| WO-2004005285-A1 | NEW QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL PRODESFARMA AG (CH) | 2004-01-15 | — | — | WO | claimed |
| US-7718670-B2 | Quinuclidine amide derivatives | LABORATORIOS ALMIRALL S.A (ES) | 2010-05-18 | — | — | US | disclosed |
| EP-1519933-B1 | QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL SA (ES) | 2010-05-12 | — | — | EP | disclosed |
| US-7488735-B2 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-10 | — | — | US | disclosed |
| US-20080234316-A1 | Quinuclidine Amide Derivatives | ALMIRALL AG | 2008-09-25 | — | — | US | disclosed |
| US-20060167042-A1 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | LABORATORIOS ALMIRALL S.A. (ES) | 2006-07-27 | — | — | US | disclosed |
| EP-1519933-A1 | QUINUCLIDINE AMIDE DERIVATIVES | Almirall Prodesfarma AG (CH) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004005285-A1 | NEW QUINUCLIDINE AMIDE DERIVATIVES | ALMIRALL PRODESFARMA AG (CH) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234316-A1 | Quinuclidine Amide Derivatives | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
| US-20060167042-A1 | antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; alkylation | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.